Table 8

The incidence case number of malignant immunoproliferativediseases and trend in crude incidence rates and age-standardized incidence rates per million population in the Republic of Korea from 1999 to 2018.

Years	N of cases				CIR	ASR^a)	ASR^a)
Years	Men	Women	Total	AAPC (%)	CIR	ASR^a)	AAPC (%)	IRR (per yr)
1999	45	50	95	14.76^b)	2.01427	2.04994	11.82^b)	1.090^b)
2000	39	39	78		1.64093	1.64093
2001	49	50	99		2.06780	2.00910
2002	98	96	194		4.03111	3.87658
2003	165	171	336		6.95531	6.50023
2004	175	174	349		7.19806	6.56316
2005	198	252	450		9.24347	8.26204
2006	212	272	484		9.90038	8.66932
2007	227	250	477		9.70887	8.37596
2008	251	327	578		11.69930	9.91273
2009	348	386	734		14.78147	12.09930
2010	315	416	731		14.65523	11.92735
2011	348	480	828		16.52316	12.85307
2012	413	471	884		17.55873	13.55260
2013	412	509	921		18.21636	13.44186
2014	437	507	944		18.59616	13.78266
2015	459	492	951		18.66473	13.50497
2016	592	603	1,195		23.37958	16.40845
2017	574	609	1,183		23.09162	15.98123
2018	601	710	1,311		25.55512	17.46422

^a)Calculated by defining the 2000 mid-year Korean population (July 1, 2000) as the standard population. ^b)Statistically significant trend (P< 0.05).

Abbreviations: AAPC, average annual percent change; ASR, age-standardized incidence rate; CIR, crude incidence rate; IRR, incidence rate ratio.

Blood Res 2021;56:301~314 https://doi.org/10.5045/br.2021.2021187